Every one of those 1 sits in a single category, market-trends. Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ICU Medical
Every one of those 1 sits in a single category, market-trends. Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention ICU Medical, all published on February 20, 2026.
Stories tracked
1
Sources per story
54
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ICU Medical. Shared-story counts are live from our verified record — not editorial picks.
A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.